Updated on 28 August 2026
In silico combinatorial therapy ranking
Tenured professor at Rīga Stradiņš University
Riga, Latvia
About
Having a genome-scale metabolic model it becomes possible to look for drugs or their combinations that disable metabolic strategies of ill tissues having less harm to healthy tissues.
Drug combinations can be ranked according to a multifactorial criterion affected by factors like 1) number of drugs in the combination, 2) expected toxicity, 3) costs and other relevant parameters depending on the application.
Topic
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
- Digital health and AI: HORIZON-HLTH-2027-03-TOOL-04 Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
Type
- Partner seeks Consortium/Coordinator
Similar opportunities
Project cooperation
Organ on chips, organoids and other NAMs for biomedical research
- Partner seeks Consortium/Coordinator
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Joude Cachoux
Business Development Manager, PharmD, MPH at Leitat Technological Center
Barcelona, Spain
Project cooperation
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Dr Raphaël Duval
CEO at THERIOPHARM
Project cooperation
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Wolfgang Fecke
Executive Director at Association of European Cancer Leagues (ECL)
Brussels, Belgium